Study on the Correlation Between Gene Mutation and TCM Syndrome Types in Metastatic Colorectal Cancer

Traditional Chinese Medicine Clinical Trial

Official title:

Study on the Correlation Between Gene Mutation and TCM Syndrome Types in Metastatic Colorectal Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04661046
• Other study ID #: SHSLCZDZK 03701
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 30, 2020
• Est. completion date: August 31, 2022

Study information

• Verified date: November 2020
• Source: Shanghai University of Traditional Chinese Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To explore the correlation between gene mutations of metastatic colorectal cancer and TCM syndrome types based on Second-generation sequencing technology.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: August 31, 2022
• Est. primary completion date: August 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. A clear pathological diagnosis is a patient with colorectal cancer;

2. Have complete TNM staging information;

3. There is a clear diagnosis of the location and time of metastasis;

4. Age =18 years old, =80 years old, male or female;

5. There is a clear time for the first treatment with Chinese medicine;

6. Patients who can receive long-term follow-up. -

Exclusion Criteria:

1. Patients with colorectal cancer diagnosed pathologically as adenosquamous carcinoma, squamous cell carcinoma, carcinoid, small cell carcinoma, malignant lymphoma, etc.;

2. Patients with double cancer, multiple or metastatic colorectal cancer;

3. Combined with severe acute and chronic diseases that may affect treatment and prognosis, such as myocardial infarction, stroke, severe renal insufficiency and mental illness;-

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Gene Mutation-Related Cancer
• Traditional Chinese Medicine

Intervention

Drug:
• Traditional Chinese Medicine
Chinese medicine prescription

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai University of Traditional Chinese Medicine

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	OS	2 years
Primary	Progression Free Survival	PFS	2 years